M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Roberto Mina,Francesca Bonello,Maria Teresa Petrucci,Anna Marina Liberati,Concetta Conticello,Stelvio Ballanti,Pellegrino Musto,Attilio Olivieri,Giulia Benevolo,Andrea Capra,Milena Gilestro,Piero Galieni,Michele Cavo,Agostina Siniscalchi,Antonio Palumbo,Vittorio Montefusco,Gianluca Gaidano,Paola Omedè,Mario Boccadoro,Sara Bringhen +19 more
TL;DR: Carrfilzomib, used both as induction and maintenance agent for transplant-ineligible newly diagnosed MM patients, mitigated the poor prognosis carried by high-risk cytogenetics and resulted in similar PFS and OS as in standard-risk patients.
Journal ArticleDOI
Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.
Constantine S. Mitsiades,Luba Benimetskaya,Krishna Menon,Cinara Echart,Cecile Rouleau,Beverly A. Teicher,Antonio Palumbo,Mario Boccadoro,Massimo Iacobelli,Kenneth C. Anderson,Cy A. Stein,Paul G. Richardson +11 more
TL;DR: In vitro studies at DF concentrations achievable in vivo were conducted to evaluate effects on growth factors critical for tumor neovascularization and pathways regulating bioavailability of extracellular matrix (ECM)-resident growth factors, and suggest that DF can perturb bioavailability, expression and/or function of diverse positive regulators of neo-angiogenesis.
Journal ArticleDOI
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
TL;DR: The treatment cessation of imatinib and tyrosine kinase inhibitor patients with chronic myeloid leukaemia is described as a “once-in-a-lifetime event” according to the World Health Organization.
Journal ArticleDOI
AgNORs and Myeloma Prognosis
TL;DR: The argyrophilic nucleolar organizer regions (AgNORs) were analysed in bone marrow biopsies from 80 patients with multiple myeloma and showed significant correlation with prognosis and can be useful additional parameters for MM prognosis.
Journal ArticleDOI
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
Stefania Oliva,Lorenzo De Paoli,Marina Ruggeri,S. Caltagirone,Rossella Troia,Daniela Oddolo,Mattia D'Agostino,Milena Gilestro,Roberto Mina,Elona Saraci,Gloria Margiotta Casaluci,Elisa Genuardi,Sara Bringhen,Mario Boccadoro,Paola Omedè +14 more
TL;DR: In this paper, the authors analyzed variations in terms of chromosomal abnormalities (CA) by fluorescence in situ hybridization (FISH) analysis on purified bone marrow plasma cells throughout the progression from monoclonal gammopathy of undetermined significance/smoldering multiple myeloma (MGUS/SMM) to newly diagnosed MM/plasma cell leukemia (NDMM/PCL) at diagnosis and from diagnostic samples to progressive disease.